Avian and seasonal influenza vaccine induced immune responses

Conditions

Avian influenza and seasonal influenza

Brief summary

Primary outcome measure: Seroconversion proportion in all study subjects 3 weeks after the second dose given at least 21 days after the first dose, as assessed by the microneutralization test

Detailed description

Rate of seroconversion defined as the percentage of subjects with either a pre-vaccination MNT titer < 1:10 and a post vaccination MNT titer ≥ 1:80 or a pre-vaccination MNT titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer., Geometric mean titers at pre- and post-vaccination, Detectable increase in T cell (CD4+ and CD8+) responses against H5N1 virus specific antigens in avian influenza virus vaccinated individuals

Liedes O, Reinholm A, Ekström N, Haveri A, Solastie A, Vara S, Rijnink WF, Bestebroer TM, Richard M, de Vries RD, Jalkanen P, Lindh E, Ikonen N, Grifoni A, Sette A, Laaksonen T, Holopainen R, Kakkola L, Lappalainen M, Syrjänen RK, Kolehmainen P, Julkunen I, Nohynek H, Melin M.

2025-12-05

10.1038/s41564-025-02183-5

Interventions

DRUGFluad Tetra

DRUGsuspension for injection in pre-filled syringe Influenza vaccine (surface antigen

DRUGinactivated

DRUGadjuvanted)

DRUGZoonotic Influenza Vaccine Seqirus suspension for injection in pre-filled syringe Zoonotic influenza vaccine (H5N8) (surface antigen

DRUGVaxigrip injektioneste

DRUGsuspensio

DRUGesitäytetty ruisku. Kolmivalenttinen influenssarokote (virusfragmentit

DRUGinaktivoitu).

DRUGFluad suspension for injection in pre-filled syringe Influenza vaccine (surface antigen

DRUGZoonotic Influenza Vaccine Seqirus suspension for injection in pre-filled syringe. Zoonotic influenza vaccine (H5N1) (surface antigen

DRUGadjuvanted).

DRUGVaxigripTetra

DRUGinjektioneste

DRUGesitäytetty ruisku. Nelivalenttinen influenssarokote (virusfragmentit

DRUGinaktivoitu)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Primary outcome measure: Seroconversion proportion in all study subjects 3 weeks after the second dose given at least 21 days after the first dose, as assessed by the microneutralization test	—

Secondary

Measure	Time frame
Rate of seroconversion defined as the percentage of subjects with either a pre-vaccination MNT titer < 1:10 and a post vaccination MNT titer ≥ 1:80 or a pre-vaccination MNT titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer., Geometric mean titers at pre- and post-vaccination, Detectable increase in T cell (CD4+ and CD8+) responses against H5N1 virus specific antigens in avian influenza virus vaccinated individuals	—

Measure

Time frame

Rate of seroconversion defined as the percentage of subjects with either a pre-vaccination MNT titer < 1:10 and a post vaccination MNT titer ≥ 1:80 or a pre-vaccination MNT titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer., Geometric mean titers at pre- and post-vaccination, Detectable increase in T cell (CD4+ and CD8+) responses against H5N1 virus specific antigens in avian influenza virus vaccinated individuals

—

Countries

Finland

Outcome results

None listed